GLP-1 hair loss is usually best understood as timeline-driven telogen effluvium (TE) rather than a mysterious “direct” follicle toxin. The key is to separate signal from mechanism: (1) the FDA’s FAERS “potential signals” list includes alopecia for GLP-1 receptor agonists, meaning FDA is evaluating the need for regulatory action, and (2) some product labels include hair loss signals either in trial tables (e.g., Wegovy) or in postmarketing experience (e.g., Ozempic, Mounjaro, Trulicity, Saxenda, Victoza). The most practical takeaway: when shedding starts 2–4 months after a trigger, TE rises to the top — and GLP-1 treatment often “stacks” TE triggers (rapid weight loss, diet shifts, illness, stress, medication changes).
Medical note: This article is for general education and does not provide personal medical advice. Do not stop GLP-1 therapy on your own. If you’re not sure whether you’re seeing shedding or breakage, start here: Shedding vs Breakage. If the diagnosis is unclear, start here: How Hair Loss Is Diagnosed. If you have scalp pain/burning, pustules/crusting, heavy scale, open sores, or rapid worsening, start here: When to See a Doctor.
Quick navigation
- Key takeaways (fast)
- What the evidence actually says (FDA + labels)
- Timeline: when shedding starts, peaks, and improves
- Why it happens (stacked triggers)
- Pattern clues: TE vs AGA vs AA vs breakage
- When labs matter (targeted workup)
- What to do (practical plan)
- When to see a doctor
- GLP-1 article index (this site)
- References
Key takeaways (fast)
- FDA signal ≠ confirmed causation: FAERS “potential signals” list includes alopecia for GLP-1 receptor agonists, and FDA states it is evaluating the need for regulatory action.
- Wegovy trial table includes hair loss: in one Wegovy adverse-reaction table, Hair Loss was reported 3% vs 1% placebo in adults.
- Postmarketing “alopecia” is labeled for multiple GLP-1 drugs: Ozempic, Mounjaro, Trulicity, Saxenda, and Victoza list alopecia in postmarketing experience.
- TE is delayed: DermNet notes increased hair fall is often noticed 2–4 months after a trigger; BAD notes it can occur around ~3 months after a trigger.
- Stacked triggers are common: DermNet and BAD both list weight loss/extreme dieting, illness/fever, surgery, stress, medications, and thyroid/iron issues as TE triggers — and GLP-1 users often have more than one of these at once.
- Related hubs on this site: Hair Shedding Hub • Medication-Related Shedding • Blood Tests & Workup.
What the evidence actually says (FDA + labels)
1) FDA FAERS “potential signal”
FDA’s FAERS “potential signals of serious risks” page lists alopecia for GLP-1 receptor agonists and states FDA is evaluating the need for regulatory action. This is a signal-monitoring step (not a proof of causation), but it is strong enough to justify structured monitoring and better patient counseling.
2) Labels: trial table vs postmarketing reports
- Trial-table example (Wegovy): Wegovy’s label adverse-reaction table lists Hair Loss at 3% vs 1% placebo in adults.
- Postmarketing alopecia examples: Ozempic, Mounjaro, Trulicity, Saxenda, and Victoza list alopecia in postmarketing experience. Postmarketing reports can’t reliably estimate frequency, but they confirm real-world reporting.
Timeline: when shedding starts, peaks, and improves
- Onset (TE logic): DermNet notes increased hair fall is often noticed 2–4 months after a triggering event; BAD notes it can occur around ~3 months after a trigger.
- Peak: TE often feels worst for several weeks once it starts.
- Recovery window: DermNet notes shedding often tapers back toward baseline over months once triggers stabilize; BAD notes the shedding phase in the cycle lasts about 3–6 months, and thickening takes longer.
Why it happens (stacked triggers)
GLP-1 therapy often changes multiple TE-relevant inputs at once. DermNet lists TE triggers including weight loss/unusual diet/nutritional deficiency, illness/fever, surgery, psychological stress, endocrine disorders (thyroid), and medications. BAD similarly lists marked weight loss and extreme dieting, illness/fever, surgery, stress, and new medications as common triggers. In practice, the question is rarely “is it the GLP-1?” — it’s “how many TE triggers stacked together?”
Pattern clues: TE vs AGA vs AA vs breakage
- Most consistent with TE: diffuse shedding (more hair in shower/brush), normal-appearing scalp, delayed timing after a trigger.
- TE + AGA overlap: if shedding slows but the part/crown keeps widening, consider pattern hair loss being “unmasked”: TE vs Androgenetic Alopecia.
- Patchy smooth bald spots: consider alopecia areata: Alopecia Areata Hub.
- Lots of short snapped hairs: consider breakage: Hair Breakage (Hair-Shaft).
When labs matter (targeted workup)
Not everyone needs labs, but in heavy, persistent, or recurrent shedding, clinicians often check for common overlaps. BAD notes blood tests may be done to exclude causes like thyroid conditions and iron deficiency. DermNet also lists nutritional deficiency (including iron) and thyroid disorders as classic TE triggers and recommends correcting abnormal thyroid function and levels of iron, vitamin B12, and folic acid when relevant.
Use your structured workup hub (order + interpretation): Blood Tests & Workup.
What to do (practical plan)
- Build a timeline: start date/dose changes + when shedding became noticeable.
- Confirm pattern: TE vs AGA overlap vs AA vs breakage (links above).
- Do not self-stop: discuss risk/benefit and alternatives with the prescriber (especially if the drug is treating diabetes).
- Unstack triggers: stabilize nutrition and avoid extreme dieting; address illness/stress; correct deficiencies if present.
- Track monthly: photos every 4 weeks (same angle/light) — not daily.
When to see a doctor
- Scalp pain/burning, pustules, heavy scale/crusting, open sores
- Patchy smooth bald spots
- Shedding persisting beyond ~6 months or recurrent waves
Start here: When to See a Doctor.
GLP-1 article index (this site)
- Wegovy Hair Loss
- Zepbound Hair Loss
- Ozempic Hair Loss
- Mounjaro Hair Loss
- Rybelsus Hair Loss
- Saxenda Hair Loss
- Victoza Hair Loss
- Trulicity Hair Loss
- Medication-Related Shedding (Hub)
References (trusted sources)
- FDA FAERS: July–September 2023 potential signals (GLP-1 agonists; alopecia)
- FDA label: Wegovy (semaglutide) — clinical trial table includes Hair Loss
- FDA label: Ozempic (semaglutide) — Postmarketing: alopecia
- FDA label: Mounjaro (tirzepatide) — Postmarketing: alopecia
- FDA label: Trulicity (dulaglutide) — Postmarketing: alopecia
- FDA label: Victoza (liraglutide) — Postmarketing: alopecia
- FDA label: Saxenda (liraglutide) — Postmarketing: alopecia
- DermNet NZ: Telogen effluvium (timing, triggers, workup)
- British Association of Dermatologists: Telogen effluvium (timing, triggers, labs)
Last updated: March 06, 2026.
